SPTX Seaport Therapeutics, Inc. - Common Stock
$24.51
Price · Aug 19, 2026
Fundamentals as of Aug 3, 2026
52W Range
$15–$26
84% of range
Analyst Rating
BUY
11 analysts
Price Target
$38
+55% upside
P/E (TTM)
—
ROE
—
Net Profit Margin
—
SPTX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$24.51
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$15 – $26
SPTX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
SPTX
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
SPTX
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
SPTX
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
SPTX
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
SPTX
Peer Median
SPTX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
11 analysts
- Strong Buy 4 36.4%
- Buy 5 45.5%
- Hold 2 18.2%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
5 analysts · 2026-08-16
Median
$35.00
Mean
$38.00
← Below all targets
$24.51
Low
$30.00
High
$50.00
Median target
$35.00
+42.8%
Mean target
$38.00
+55.0%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-2.6%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| June 30, 2026 | $-0.73 | $-0.63 | -0.10% |
| March 31, 2026 | $-10.34 | $-5.28 | -5.1% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| SPTX | — | — | — | — | — | — |
| LBRX | $563M | -7.1 | — | — | -25.5% | — |
| HROW | $1.82B | -350.0 | 36.4% | -1.9% | -8.4% | 75.0% |
| XERS | $1.30B | — | 43.7% | 0.19% | -19.7% | — |
| PAHC | — | 21.5 | 27.4% | 3.7% | 17.8% | 30.9% |
| ANRO | $568M | -8.1 | — | — | -46.1% | — |
| EYPT | $1.51B | -5.8 | -27.5% | -739.4% | -84.0% | — |
| OMER | $1.23B | -343.6 | — | — | 1.9% | — |
| LXRX | $421M | -8.2 | 60.2% | -101.1% | -39.7% | — |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Balance Sheet 19
| Metric | Trend | 2025 |
|---|---|---|
| Cash & Equivalents | $46M | |
| Short-term Investments | $170M | |
| Prepaid Expense | $7M | |
| Current Assets | $223M | |
| PP&E (Net) | $412.0K | |
| PP&E (Gross) | $1M | |
| Accum. Depreciation | $989.0K | |
| Other Non-current Assets | $3M | |
| Total Assets | $249M | |
| Accounts Payable | $2M | |
| Current Liabilities | $13M | |
| Capital Leases | $3M | |
| Total Liabilities | $16M | |
| Common Stock | $1.0K | |
| Retained Earnings | $-114M | |
| AOCI | $301.0K | |
| Stockholders' Equity | $-93M | |
| Liabilities + Equity | $249M | |
| Shares Outstanding | 2,595,342 |
Income Statement 13
| Metric | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| R&D Expense | $25M | $21M | |
| SG&A Expense | $41M | $6M | |
| Operating Expenses | $66M | $28M | |
| Operating Income | $-66M | $-28M | |
| Other Non-op | $3M | $3M | |
| Pretax Income | $-62M | $-25M | |
| Income Tax | $251.0K | $519.0K | |
| Net Income | $-63M | $-25M | |
| EPS (Basic) | $-1.78 | $-10.34 | |
| EPS (Diluted) | $-1.78 | $-10.34 | |
| Shares (Basic) | 35,236,214 | 2,456,766 | |
| Shares (Diluted) | 35,236,214 | 2,456,766 | |
| EBITDA | $-66M | $-28M |
Balance Sheet 19
| Metric | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| Cash & Equivalents | $64M | $53M | |
| Short-term Investments | $209M | $130M | |
| Prepaid Expense | $9M | $6M | |
| Current Assets | $282M | $188M | |
| PP&E (Net) | $360.0K | $386.0K | |
| PP&E (Gross) | $1M | $1M | |
| Accum. Depreciation | $1M | $1M | |
| Other Non-current Assets | $454.0K | $4M | |
| Total Assets | $442M | $228M | |
| Accounts Payable | $6M | $5M | |
| Current Liabilities | $16M | $14M | |
| Capital Leases | $3M | $4M | |
| Total Liabilities | $19M | $18M | |
| Common Stock | $5.0K | $1.0K | |
| Retained Earnings | $-202M | $-140M | |
| AOCI | $-475.0K | $64.0K | |
| Stockholders' Equity | $423M | $-116M | |
| Liabilities + Equity | $442M | $228M | |
| Shares Outstanding | 53,530,550 | 2,595,342 |
Cash Flow 6
| Metric | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| Operating Cash Flow | $-26M | $-20M | |
| CapEx | $0 | $0 | |
| Investing Cash Flow | $-204M | $28M | |
| Financing Cash Flow | $241M | $-783.0K | |
| Net Change in Cash | $11M | $7M | |
| Free Cash Flow | · | $-20M |
Profitability 3
| Metric | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| ROA | -28.3% | -22.3% | |
| ROE | -29.6% | 44.0% | |
| ROIC | -15.6% | 24.3% |
Liquidity & Solvency 2
| Metric | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| Current Ratio | 18.0 | 13.2 | |
| Quick Ratio | 17.4 | 12.8 |
Valuation (TTM) 3
| Metric | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| Market Cap | $1.16B | · | |
| P/B | 2.8 | · | |
| P / Tangible Book | 2.8 | · |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Company insiders 12 insiders · 5 officers · 8 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Daphne Zohar | Chief Executive Officer | April 30, 2026 A | — | 0 | 0 | $0 |
| Lauren White | Chief Financial Officer | May 4, 2026 C | 6,702 | 0 | 0 | $0 |
| Michael Cunyuan Chen | Chief Scientific Officer | May 4, 2026 C | 3,351 | 0 | 0 | $0 |
| Lana Gladstein | General Counsel | May 4, 2026 C | 33,515 | 0 | 0 | $0 |
| Antony Loebel | Chief Medical Officer | May 4, 2026 C | 20,109 | 0 | 0 | $0 |
| Robert J. Hombach | Director | June 22, 2026 P | 13,000 | 1 | 0 | $235,820 |
| Denice Torres | Director | May 4, 2026 C | 13,406 | 0 | 0 | $0 |
| Dr. James I. Healy | Director | May 4, 2026 C | 2,731,538 | 0 | 0 | $0 |
| Steven M Paul | Director | May 4, 2026 C | 863,031 | 0 | 0 | $0 |
| David E. Wheadon | Director | April 30, 2026 A | — | 0 | 0 | $0 |
| Sharon Mates | Director | April 30, 2026 A | — | 0 | 0 | $0 |
| Sandra E Peterson | Director | April 30, 2026 A | — | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 2 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| General Atlantic, L.P., General Atlantic (SPV) GP, LLC, General Atlantic Partners 100, L.P., General Atlantic (SP), L.P., General Atlantic Partners (Lux) SCSp, General Atlantic GenPar, L.P., GAP Coinvestments III, LLC, GAP Coinvestments IV, LLC, GAP Coinvestments V, LLC, GAP Coinvestments CDA, L.P., General Atlantic GenPar (Lux) SCSp, General Atlantic (Lux) S.a r.l., General Atlantic GenPar (Bermuda), L.P., GAP (Bermuda) L.P. | May 11, 2026 | 11.50% | Initial filing | Passive investment | SEC |
| ARCH Venture Fund XII, L.P., ARCH Venture Partners XII, L.P., ARCH Venture Partners XII, LLC, Robert Nelsen, Keith Crandell, Kristina Burow, Steven Gillis | May 6, 2026 | 11.90% | Initial filing | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF ownership Held by 6 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| VXF · VANGUARD INDEX FUNDS | 0.00% | 165,436 SH | Aug. 8, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 426,371 SH | Aug. 8, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.00% | 7,907 SH | Aug. 8, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.00% | 240 SH | Aug. 8, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.00% | 778 SH | Aug. 8, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 156 SH | Aug. 8, 2026 | Daily |